Podcast appearances and mentions of cristina rodriguez

In this episode, I'm thrilled to welcome back Cristina Rodriguez, a Licensed Marriage and Family Therapist from Tulare, California, with over 11 years of experience in the field. Cristina joins me for a deep dive into three powerful and transformative therapeutic approaches: Play Therapy, EMDR, and Internal Family Systems (IFS).We break down what these methods are, how they work, and the real impact they can have on clients' lives. Whether you're a mental health professional, a parent curious about effective therapeutic tools, or someone on your own healing journey, this episode is packed with valuable insights you won't want to miss.

Sandi Morgan Caesar is a transnational adoptee. She was born Cristina Rodriguez in Panamá to a 14-year-old girl who parented her for most of her 1st year. Ultimately, she was placed for adoption by her maternal grandmother without the knowledge or consent of her first mother. Sandi was adopted by a Black US Air Force family stationed in Panamá at the time. She was naturalized as a US citizen and then brought to the US at 3 years old. It was about this time that she asked her mom why they didn't have the same face. She grew up in Dayton, Ohio, with older siblings (biological to her adoptive father). Although she thought finding family in Panamá would be impossible, Sandi reunited with her birthmother and maternal family in 2004. Sandi holds a B.S. degree in Human Development from Howard University, an M.S.W. from Indiana University, and has worked in child welfare most of her career.Sign up for our mailing list to get updates and the Eventbrite - (soon to be published) - for our September 12th & 13th Washington, D.C. Event!Thank you to our Patreons! Join at the $10 level and be part of our monthly ADOPTEE CAFE community. The next meeting will be on Saturday, June 7th, @ 1 PM ET.RESOURCES for Adoptees:S12F Helping AdopteesGregory Luce and Adoptees Rights LawFireside Adoptees Facebook GroupDr. Liz Debetta: Migrating Toward Wholeness MovementMoses Farrow - Trauma therapist and advocateNational Suicide Prevention Lifeline – 1-800-273-8255 OR Dial or Text 988.Unraveling Adoption with Beth SyversonAdoptees Connect with Pamela KaranovaBecause She Was Adopted by Kristal ParkeDear Amy, letters to Amy Coney Barrett. A project by Meika RoudaSupport the showTo support the show - Patreon.

Earlier this year, President Trump signed an executive order aimed at ending birthright citizenship. He has placed this issue at the forefront of his immigration agenda and it is now being taken up by the Supreme Court. To have this conversation, we've brought together a constitutional law scholar and a political commentator.Cristina Rodríguez is the Leighton Homer Surbeck Professor of Law at Yale Law School. In 2021, she was appointed by President Biden to co-chair the Commission on the Supreme Court of the United States. Her recent book is called The President and Immigration Law. She's also the co-host of the new podcast: Unsettled: Immigration in Turbulent Times.Rod D. Martin writes The Rod Martin Report on Substack. He is also the Founder and CEO of Martin Capital. As a tech entrepreneur and venture capitalist, Rod was previously an advisor to Peter Thiel. Rod also served as policy director to Mike Huckabee, the former Governor of Arkansas.We talk a lot about the 14th Amendment in this episode. It was ratified in 1868 to give formerly enslaved people the right to vote. Here's what it says: “all persons born or naturalized in the United States, and subject to the jurisdiction thereof, are citizens of the United States.” Keep that phrase in mind. “Subject to the jurisdiction thereof.” It'll come up a lot.Our guests also discuss the Supreme Court cases Elk v Wilkins, Slaughterhouse, and Wong Kim Ark. All you need to know for this episode is: those rulings influenced the interpretation of the 14th Amendment. Last note, this episode is moderated by co-host and co-founder, Catherine Cushenberry. Questions or comments about this episode? Email us at podcast@thedisagreement.com or find us on X and Instagram @thedisagreementhq. Subscribe to our newsletter: https://thedisagreement.substack.com/

Si estás interesado(a) en convertirte en un Coach Certificado en la Metodología EGM™️ puedes visitar el siguiente enlace: Certificarme como Coach EGM™️Puedes seguirnos en nuestro Instagram aquí: Instagram EGM™️Para aprender sobre el Método EGM™️ visita: www.metodoegm.com Hosted on Acast. See acast.com/privacy for more information.

Llega una semana más a tu moda, con Genel Romero, hablamos de moda, noticias, entrevistas con Cristina Rodriguez y Rául Rodriguez.

ASCO: You're listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the voice of the world's oncology professionals. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guests' statements on this podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so data described here may change as research progresses. The theme of the 2023 ASCO Annual Meeting was “Partnering With Patients: The Cornerstone of Cancer Care and Research.” From June 2 to 6 in Chicago, Illinois, and online, cancer researchers and clinicians from around the world gathered to discuss the latest cancer research and how to ensure that all people receive the cancer care they need. In the Research Round Up series, members of the Cancer.Net Editorial Board discuss the most exciting and practice-changing research in their field presented at the meeting and explain what it means for people with cancer. In today's episode, our guests will discuss new research in gynecologic cancers [2:06], multiple myeloma [9:15], and head and neck cancer [16:03]. First, Dr. Lan Coffman discusses new research in ovarian cancer, uterine cancer, and cervical cancer. Dr. Coffman is a physician-scientist and gynecologic oncologist at the Magee-Womens Research Institute and Foundation, and assistant professor in Hematology-Oncology at the University of Pittsburgh School of Medicine. She is also the 2023 Cancer.Net Associate Editor for Gynecologic Cancers. You can view Dr. Coffman's disclosures at Cancer.Net. Dr. Coffman: Hi, my name is Lan Coffman. I'm a physician-scientist at the University of Pittsburgh. I'm a medical oncologist that specializes in gynecologic cancers, and I'm happy to discuss research that was presented on gynecologic cancers at the 2023 ASCO Annual Meeting. I do have a relevant disclosure. I participated in one of the trials I'm going to discuss, a trial called MIRASOL. I was the site principal investigator at University of Pittsburgh. I think there were a lot of interesting studies to highlight, and I wanted to focus on studies involving ovary cancer, endometrial cancer, and cervix cancers as the main sites that we study in the gynecologic oncology world. So when we talk about ovary cancer, I think there was one really impactful study that was presented at ASCO this year, and it was called MIRASOL. And again, this is the study that I also participated in at our hospital at University of Pittsburgh. So it was a large study, so a randomized phase 3 study looking at a drug called mirvetuximab, which is an antibody-drug conjugate. So basically, it's an antibody against a protein that is expressed on ovarian cancer cells and the protein's called folate receptor-alpha. And that antibody basically carries a little poison. And so it's kind of like a Trojan horse. This antibody goes, finds that protein on the tumor cells, and then delivers that poison. And so this drug has been studied and actually was presented last year in a different trial called SORAYA, which showed that it had activity, meaning the drug helped to kill ovarian cancer cells, and actually led to the first approval of this drug in ovary cancer. So this trial was the confirmatory trial, so enrolling more patients to see, actually, is it better than standard-of-care chemotherapy? So this was in women with ovarian cancer that had come back and was platinum resistant, meaning the cancer started to grow within 6 months from the last platinum-based therapy. Women were eligible if they had high expression of this folate receptor-alpha, and they had to have a couple of prior lines of therapy. And then they were randomized, so kind of chosen out of a hat to either be treated with mirvetuximab or with investigator's choice chemotherapy. So one of the chemotherapies we'd use standardly. And so that would be something like taxol, or liposomal doxorubicin, or topotecan. And basically, this study was comparing how well does mirvetuximab work compared to chemotherapy. And importantly, it showed that it improved survival, both progression-free survival, so how long it took before the disease started to grow again, but probably more importantly, actually improved overall survival, so how long a woman lived. And actually changed overall survival from about 16 and a half months compared to 12 months with chemotherapy. And so this was really important and demonstrated that mirvetuximab does actually impact women with ovarian cancer and actually helps women live longer. And that's really hard to do in this setting. And the other nice thing about this trial was that not only did it work well, but there are actually lower side effects with it, and so less women actually had to discontinue their treatment, and they had less what we call adverse events, or basically bad things that had happened from the treatment themselves. So just telling us that this drug is actually well tolerated. Women feel well on it, even when their cancer is shrinking. So I think that was one of the most impactful studies in ovary cancer. Moving on to endometrial cancer. We recently had 2 studies, one called RUBY and one called GY018 that looked at using immunotherapy in combination with chemotherapy in endometrial cancer. And what was presented at ASCO was some follow-up from this RUBY trial, which was basically validating that this combination of adding immunotherapy actually helped. To give you a background, traditionally, women that have endometrial cancer that is advanced staged, meaning spread outside of the uterus itself or has come back, we treat it with chemotherapy. But this study added an immunotherapy called dostarlimab in combination with our standard chemotherapy and actually showed that women were living longer with this, at least in that progression-free survival. We're still waiting on final evaluation. But at ASCO, what they reported was another independent blinded review of the data to show that even when we're really carefully looking at this data, it looks like immunotherapy helps women with endometrial cancer live longer. They also presented quality-of-life data showing that women actually feel better with the addition of the immunotherapy. So I think this is practice changing. And again, this data has been coming out over the last year or so, but I do think this will change the way in which endometrial cancer is treated. And then the final thing I wanted to discuss would be in cervix cancer. And while there wasn't a lot of new data presented here in terms of kind of paradigm shifts or large changes, we did have final survival [data] from the KEYNOTE-826 presented, which is also using immunotherapy along with chemotherapy in cervix cancer. And so this was in women that, again, had advanced-stage cervix cancer. So it was a cervix cancer that had moved beyond the cervix itself or cervix cancer that had come back and was treated with chemotherapy along with another immunotherapy called pembrolizumab. And this was the final survival data that confirmed that the immunotherapy did help women live longer. The survival data was impressive with about a 10-month improvement in overall survival. So how long a woman lived. And so that was really confirmatory of the previous trials. So again, that emphasizes that immunotherapy is moved towards the standard of care in cervix cancer as well. I can't hit all the highlights of the impressive research coming out of ASCO 2023, this is a brief summary of some of the critical studies in gynecologic cancers. ASCO: Thank you, Dr. Coffman. Next, Dr. Sagar Lonial discusses new research in multiple myeloma. Dr. Lonial is a professor of Hematology and Medical Oncology at Winship Cancer Institute at Emory University, where he also serves as Department Chair. He is also the 2023 Cancer.Net Associate Editor for Myeloma. You can view Dr. Lonial's disclosures at Cancer.Net. Dr. Lonial: Hello, I'm Dr. Sagar Lonial from the Emory School of Medicine and the Winship Cancer Institute in Atlanta, Georgia. And today I'm going to discuss some of the really exciting research in the context of multiple myeloma that was presented at the 2023 ASCO Annual Meeting. In terms of my conflicts of interest, I have enrolled patients on many CAR T trials as well as bispecific trials from all of the different companies involved here. So, I do have some engagement with those trials. And one of the studies that I may talk about at the end came from our institution. So I was an investigator on that study as well. When I think about some of the really exciting work that was presented at ASCO this year, there are really 2 big categories of trials that I think were most exciting. And the first is CAR T-cells and moving them earlier and earlier in the disease state. And what we saw at ASCO this year was the CARTITUDE-4 study, which was a randomized phase 3 trial comparing CAR T-cells versus standard treatment in the context of first or second relapsed multiple myeloma. And this was a really important study for us to hear because we know that CAR T-cells are highly effective in the later lines of therapy. A big question at this point is, "Does their efficacy hold up in earlier lines of therapy? And how does it compare in a randomized setting against what we might normally use in that clinical context?" And what I think we were really excited to see at ASCO this year was that CAR T-cells appear to be superior to standard treatment in the context of that randomized phase 3 trial. Now, there were a few patients who were randomized to CAR T-cells who didn't get to the CAR T-cell infusion because their disease progressed in that interval. And that is a challenge that many of us deal with on a regular basis when we think about using a CAR T in a patient. But in general, the treatment was available for almost all patients. And the analysis of benefit as measured by a longer remission duration for the patients who received CAR T cells versus those who didn't was really done on what we call an intent to treat basis. And what that means is if you were randomized to the CAR T arm, even if you didn't get the CAR T, which again was a very small number of patients, you were still evaluated as if you got a CAR. And what I think that tells us is that even taking into account some of those patients who may not get there, there still was significant clinical benefit. And this is really important data for us to have insight into. We've seen this with cilta-cel in CARTITUDE-4. We'd seen similar kinds of findings in KarMMa using ide-cel as the CAR T-cell, although it does appear that the remission duration, at least when you're comparing across trials, appears to be a little bit longer for cilta-cel than what we've seen with ide-cel. But nonetheless, it suggests that even in the context of early relapse, there may be some benefit for CARs over standard therapy. Now, does this mean that CARs are going to replace standard therapy in terms of early relapse? I don't think we know the answer to that right now. I think there's a lot of information that we need to look at to really feel comfortable making that step. The other big set of data I think that we were all very excited about to see at ASCO this year were the T-cell engagers or the bispecifics. And what we saw from a number of different bispecifics was that the efficacy data looks like it continues to hold up. But what to me was really quite exciting was the idea that the T-cell engager could be highly effective even if a patient had seen prior BCMA-directed therapy. And what this means to me is that perhaps if you're progressing on a CAR T-cell, you still may have a pretty reasonable chance at a response, again, to a BCMA-directed therapy with a bispecific. The other way around may not necessarily be the same. And so I think what we learned at this meeting is that the bispecific or T-cell engagers clearly could have activity in the context of prior BCMA-exposed therapy. And I think, as a field, we need to think more about how we define what it means to be resistant to a BCMA-directed therapy. So that I think was really important and exciting and will have relevance in our daily clinical practice. We also saw updates on a different non-BCMA-directed target. So we saw updates on GPRC5D-targeted bispecifics, also known as talquetamab. What I think was really exciting here is we saw a very high overall response rate, modest infectious complications compared to what we've seen with BCMA-directed therapy.   Finally, what I want to wrap up with was a very small study addressing what I think is a pretty significant unmet medical need. And that was a trial from Dr. Nooka at my institution, where we evaluated a combination of carfilzomib with pomalidomide and dexamethasone, or KPD. And we used that specifically as maintenance in the high-risk group. And what we learned from that evaluation is that it appears for patients with high-risk disease that KPD maintenance is better than either carfilzomib and len [lenalidomide] or even bortezomib and lenalidomide, which historically has been what we're using. But there remains an unmet medical need patient population, particularly the double-hit patient population, that even with KPD still didn't have a great outcome overall. So more work for us to do down the road. But certainly, food for thought for many of those other patients that perhaps don't fit into that double-hit classic category. So I think what I've given you is a nice sort of overview of many of the exciting data that were presented at ASCO 2023. Again, go to the website to see additional ones. And thank you again for listening to this brief summary of research in myeloma updates from the 2023 ASCO Annual Meeting. ASCO: Thank you, Dr. Lonial. Finally, Dr. Cristina Rodriguez discusses new research in treating head and neck cancer. Dr. Rodriguez is a medical oncologist at Seattle Cancer Care Alliance, an Associate Professor in the Division of Medical Oncology at the University of Washington, and an Associate Member for solid tumor clinical research at the Fred Hutchinson Cancer Research Center. She is also the 2023 Cancer.Net Associate Editor for Head and Neck Cancers. You can view Dr. Rodriguez's disclosures at Cancer.Net. Dr. Rodriguez: Hello, my name is Cristina Rodriguez, and today I'm going to discuss some new research focusing on head and neck cancer that was presented at our annual ASCO 2023 meeting. As part of my disclosures, my institution receives research funding from CGEN. My takeaway from this meeting was there were a few major themes represented by the research. One of them was research on uncommon cancer types, such as nasopharyngeal cancer and salivary gland cancer. The other major theme and what was exciting for me was research on groups that were typically not represented in clinical trials in head and neck cancer. These include elderly or frail patients with many other comorbid illnesses that might have excluded them from clinical trials. Another theme was research in areas outside the developed world. In other words, resource-restricted countries. There was some exciting research coming out of that. And finally, a few new agents, novel agents that looked to have activity in patients with head and neck cancer that are going to be studied further. So with that, I'm going to start with talking about research that came out of France, presented by Dr. Fayette. This was a clinical trial that focused primarily on the frail elderly population. A group that might make very difficult for one to enter clinical trial because of many different illnesses or not being fit enough. And this group, out of France, looked at a combination of immunotherapy and a gentler lower dose chemotherapy called carboplatin and paclitaxel. Interestingly, in this group, there was very encouraging results, including 71% of patients having an objective response or a reduction in the size of their tumor, and very few patients, less than 5% of patients, having toxicity that required permanent discontinuation of the drug. So I thought this study was particularly interesting and gives us physicians and patients who are in this situation some more options to use when we're in the treatment of head and neck cancer. The next study that I thought was particularly interesting came out of India and was presented by Dr. Kothari. The special thing about this study was that it asked the question of the efficacy of a very low-cost combination for patients with recurrent or metastatic head and neck cancer. It's a combination that we don't tend to use here in the United States, one that involves methotrexate, celecoxib, and erlotinib. This particular clinical trial was carried out in several sites in India, and it randomized patients to this low-cost oral regimen versus physician's choice. In other words, any type of treatment that might involve immunotherapy or antibody therapy. The main issue here being that sometimes many of these therapies are not easily accessible to patients in low-resourced situations. The investigators observed an overall survival advantage, what that means is more patients lived longer when they use the low-cost oral regimen, which was much more practical, much easier for patients to take, and had more success in improving and prolonging the lives of patients. So I thought that that was a particularly important observation. And we forget a lot of times when we're practicing in the United States that a lot of our practice patterns here may not be applicable to low-resource settings. And I think it's very exciting that research is being carried out to answer questions that are relevant to this area. The third abstract that I thought was particularly intriguing was one presented by Dr. Glenn Hanna from Dana-Farber. And it looked at a new drug called BCA101. BCA101 is an antibody that has 2 functions. It inhibits EGFR, or epidermal growth factor receptor, very commonly overexpressed in head and neck squamous cell carcinomas. And it has a dual function, which is it modulates TGFβ, which is an immunosuppressive cytokine within tumor cells. This drug was combined with pembrolizumab in this small study and offered to patients who have never received treatment for recurrent or metastatic head and neck cancer. There was a lot of enthusiasm for this drug because in the 33 patients enrolled in the trial, 48% of them had an objective response, meaning a reduction in the size of their tumor. Anemia was one of the more common side effects that were noted. But the efficacy of this agent in this population, these patients expressed PD-L1 or had a CPS score of 1, was enough to support further study of this drug and a larger clinical trial is going to be carried out looking to see if this drug will have similar efficacy or better efficacy in a larger population. Finally, the last abstract is one that was presented by Dr. Swiecicki. And it was an interesting abstract to me because it examined the activity of another novel agent not FDA-approved for head and neck cancer, called enfortumab vedotin. This is a class of drugs that belong to a group called antibody-drug conjugates. This is an antibody that's directed toward the target called Nectin-4 and has a small chemotherapy payload that's attached to the antibody. Unlike Dr. Hanna's study, this study was a small phase 2 trial that focused on patients who've previously been treated in the recurrent or metastatic setting and are now receiving this drug either as their second or third option after they developed recurrent or metastatic disease. 46 patients were enrolled in this trial, and 24% of patients had an objective response or reduction in the size of this tumor. Although that number doesn't seem very high, it is an encouraging signal because in patients who previously received treatment for head and neck cancer, we tend to see very poor response rates. So this is encouraging given the population that was studied. Another 32% of these patients had what's called stable disease or no significant change in the size of their tumor. So that too is quite encouraging. This drug is going to also move on for further study in head and neck cancer. So I thought that these themes really brought about a lot of excitement for me for the future of treatments in patients with head and neck cancer, not only in developed countries but also in resource-restricted environments. And I look forward to next year and more work being done in these areas. And I'd like to thank you for listening to this brief summary of developments and head and neck cancer presented in the 2023 ASCO Annual Meeting. ASCO: Thank you, Dr. Rodriguez. You can find more research from recent scientific meetings at www.cancer.net. Cancer.Net Podcasts feature trusted, timely, and compassionate information for people with cancer, survivors, and their families and loved ones. Subscribe wherever you listen to podcasts for expert information and tips on coping with cancer, recaps of the latest research advances, and thoughtful discussions on cancer care. And check out other ASCO Podcasts to hear the latest interviews and insights from thought leaders, innovators, experts, and pioneers in oncology. Cancer.Net is supported by Conquer Cancer, the ASCO Foundation, which funds lifesaving research for every type of cancer, helping people with cancer everywhere. To help fund Cancer.Net and programs like it, donate at CONQUER.ORG/Donate.

This week a U.S. public health measure known as Title 42 came to an end. The U.S. is supposed to allow people fleeing persecution to seek asylum. But Title 42 allowed the Department of Homeland Security to turn away asylum-seekers if detention centers lacked the room to hold them during the asylum vetting process. The policy made it difficult for migrants to even apply for asylum in the first place. They would often be released back into Mexico. But now, the old rules are back in place, and thousands of asylum seekers who have been stuck in limbo are poised to seek asylum again.The Biden administration is also rolling out a new set of policies designed to address asylum claims before migrants physically reach the U.S. border. It's created a mobile app which people can use to schedule an appointment with immigration officials and the State Department is working on plans to open regional processing centers throughout the Western hemisphere.  The new measures could upend a simple idea at the heart of a complex immigration system: that people fleeing violence and persecution have the chance to find refuge in the United States. That change has massive implications for those who live in the U.S. and those trying to reach it.  To help us understand the end of Title 42 and what comes next we have Adam Cox, Michelle Hackman, and Cristina Rodriguez. Michelle is a reporter who covers immigration at the Wall Street Journal. Adam and Cristina are law professors at NYU and Yale respectively. They wrote a book called “The President and Immigration Law.”  Show Notes: Adam Cox (@adambcox) Michelle Hackman (@MHackman)Cristina Rodríguez (@cmrodriguez95)Adam and Cristina's Just Security article analyzing the end of Title 42Just Security's asylum coverageMichelle's Wall Street Journal reporting  32:18 NYU's American Journalism Online ProgramMusic: “The Parade” by “Hey Pluto!” from Uppbeat: https://uppbeat.io/t/hey-pluto/the-parade (License code: 36B6ODD7Y6ODZ3BX)

In episode 2 of the People of Hitachi podcast, Mary-Jane Lintin meets Lan Lin & Cristina Rodriguez-Vera, two members of Hitachi Europe's Research and Development team, to discuss the exciting project they entered for Hitachi's largest internal awards programme. Please subscribe and leave us a five star review (it really helps people find us!) and we'll be back next Tuesday with another episode. Music by Jago Thornton.See omnystudio.com/listener for privacy information.

After a woman discovers her brother's brutally beaten body on his bathroom floor, Texas police follow clue after clue and weave together a tale of greed, deception, and manipulation.Season 29, Episode 12Originally aired: June 20, 2021Watch full episodes of Snapped for FREE on the Oxygen app: https://oxygentv.app.link/WatchSnappedPodSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

ASCO: You're listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the voice of the world's oncology professionals. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guests' statements on this podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so data described here may change as research progresses. In the Research Round Up series, ASCO experts and members of the Cancer.Net Editorial Board discuss the most exciting and practice-changing research in their field and explain what it means for people with cancer. In today's episode, our guests will discuss new research in head and neck cancer, brain tumors, and health equity that was presented at the 2022 ASCO Annual Meeting, held June 3-7 in Chicago, Illinois. First, Dr. Cristina Rodriguez will discuss 2 studies on new treatment options for locally advanced head and neck cancer. Dr. Rodriguez is a medical oncologist at Seattle Cancer Care Alliance, an Associate Professor in the Division of Medical Oncology at the University of Washington, and an Associate Member for solid tumor clinical research at the Fred Hutchinson Cancer Research Center. She is also the Cancer.Net Associate Editor for Head and Neck Cancers. You can view Dr. Rodriguez's disclosures at Cancer.Net. Dr. Rodriguez: Hello. My name is Christina Rodriguez. I'm a medical oncologist with a clinical and research focus on head and neck cancer. And today I'm going to discuss research on head and neck cancer that was presented at the most recent 2022 ASCO Annual Meeting. I don't have any relationship to disclose that pertains to the research that I will talk about today. I'd like to discuss 2 abstracts that I thought were practice changing or practice affirming that really addresses some of the key questions that patients and doctors like me have about the treatment of patients with head and neck cancer. So, as you know, most patients with head and neck cancer present with typically locally advanced disease, and most head and neck cancer patients are treated with the intent of curing them most of the time with the use of radiation either as the main treatment or after surgery. And many clinical trials have shown that when we add a chemotherapy called cisplatin to radiation, we improve curative outcomes for patients. But the first abstract that I will talk about, abstract 6003, asks the question "What do we do for patients who are not candidates for cisplatin chemotherapy?" And we know that a significant proportion of our patients will have other medical problems that could make it difficult for us to give chemotherapy and often will result in complications or more toxicity or in side effects for patients. This clinical trial was carried out in India, and it compared radiation alone for patients with head and neck cancer versus radiation given with a non-cisplatin chemotherapy called docetaxel. What's unique about this clinical trial is that it's specifically focused on patients who were not candidates for cisplatin chemotherapy, something that really hasn't been done for this population. Interestingly enough, they found that when we give docetaxel with radiation in these patients, we find that they do better, they live longer, and they feel better based on quality-of-life questionnaires. So I will say that this study, abstract 6003, tells us that even in patients who are not candidates for cisplatin to be given with radiation, there is an alternative treatment that we can use, such as docetaxel given with radiation, that might still improve patient's cure rates for their head and neck cancer. The second study that I think was another interesting study was a clinical trial that asked the question, "Can we give cisplatin in an alternative manner for patients who are undergoing definitive radiation treatment as their main treatment for head and neck cancer?" Like I mentioned, the clinical trials that led to the use of chemoradiation as a standard use cisplatin given in larger doses every 3 weeks, but there's been concern about how well that approach is tolerated by patients. So this particular clinical trial compared patients receiving radiation as curative intense therapy for head and neck cancer with either the cisplatin given every  3 weeks or the cisplatin given at a lower dose once a week. It's important to know that this trial was done in India, where the population is pretty different from what we see in the United States. These are mostly patients who have HPV-negative cancers, mostly cancers acquired through exposures like tobacco and alcohol. And what they found was that these 2 groups of patients had very similar outcomes. In other words, there didn't seem to be a reduction in the rates of cure when we give chemotherapy every week versus every 3 weeks. And interestingly enough, it looked like from a toxicity or side effect standpoint, the every week seems to be a little bit better tolerated. Patients who got the treatment every 3 weeks also had less need for hospitalization or IV fluids and less utilization of health care resources. I think this is a very interesting finding because it really provides us with what we call high-level data that the weekly administration can work. I think it's important to recognize that the population that it studied for this particular clinical trial really was more an HPV-negative population. That's important to know because the standards for HPV-positive head and neck cancer are generated from larger trials that use cisplatin every 3 weeks. But we are continuing to study this question, and there's actually a large NRG study, HN009, that is asking that question both for the HPV- positive and HPV- negative population. So we are, I think, making strides in terms of asking the questions that allow our patients not only to receive treatment that is highly efficacious but also that limits side effects and toxicity. I will also mention that these trials were completed during the COVID-19 pandemic, which tells you that the dedication of these researchers to complete something like this in such a challenging time is to be commended. That's all I have to say, and thank you for listening to this brief summary of new research in head and neck cancer from the ASCO 2022 Annual Meeting. ASCO: Thank you, Dr. Rodriguez. Next, Dr. Glenn Lesser will discuss 3 studies that looked at new treatments for different types of brain tumors. Dr. Lesser is the inaugural Louise McMichael Miracle Professor and Associate Chief in the section on Hematology and Oncology in the Department of Internal Medicine at Wake Forest Health. He is also the Cancer.Net Associate Editor for Central Nervous System Tumors. You can view Dr. Lesser's disclosures at Cancer.Net.   Dr. Lesser: Hello. My name is Glenn Lesser, and I'm a professor of medical oncology and the director of medical neuro-oncology at the Wake Forest Baptist Comprehensive Cancer Center in Winston-Salem, North Carolina. I'm also the editor of the brain tumor section for ASCO's Cancer.Net. And today, I would like to briefly discuss several clinically relevant research studies involving patients with brain tumors that were presented at this year's ASCO Scientific Program. Of note, I have no disclosures or relationships relevant to the abstracts I'll be discussing today. The first presentation to talk about is a late-breaking abstract presented by Dr. Eric Bouffet, who described the results of a phase II trial of 2 targeted anticancer agents, dabrafenib and trametinib, in pediatric patients with a kind of brain tumor called a low-grade glioma, which harbored something called a BRAF V600E mutation in their tumor DNA. By way of background, gliomas account for about 45% of all pediatric brain tumors, and the majority of these gliomas are low-grade, which include World Health Organization grade 1 and 2 tumors. Common types of pediatric low-grade gliomas include pilocytic astrocytomas, gangliogliomas, and low-grade gliomas that are not otherwise specified. Now, mutations in the BRAF gene are common in certain kinds of cancers, particularly melanoma, and novel oral targeted therapies have been developed to effectively treat these tumors by targeting this mutant BRAF gene. A particular mutation in this gene called a V600E mutation occurs in about 15% to 20% of pediatric low-grade gliomas. The presence of this mutation is thought to lead to an increased risk of progression to a higher grade or a more malignant glioma in these patients, and these mutations in their tumors also predict a less favorable response to chemotherapy. In adults, recent studies in patients with malignant gliomas, papillary craniopharyngiomas, and melanomas containing V600E mutations have shown excellent results, with 1one of several similar 2-drug combinations that target both the V600E mutation and a second pathway that cells use to escape from this BRAF blockade. Now, early pediatric data suggested that one of these pairs of drugs, the combination of dabrafenib and trametinib, was safe and tolerable and had the ability to effectively treat patients whose tumors had the V600E mutation. So with that as background, this study was started and enrolled patients from 12 months to 18 years of age who had a low-grade glioma that contained a BRAF V600E mutation. And it randomized them to receive either the combination of dabrafenib and trametinib, or an older, standard cytotoxic chemotherapy regimen consisting of carboplatin and vincristine. Importantly, these patients were newly diagnosed, and this was the first systemic treatment they got, following their surgery or biopsy. 110 patients were enrolled, with 73 given the new targeted therapy combination and 37 receiving the standard combination. The most common types of tumors that the patients enrolled on this study had included pilocytic astrocytoma, ganglioglioma, and low-grade glioma. The results of this trial were that the patients who received the newer combination, targeted treatment of dabrafenib and trametinib, did substantially better than those who received standard, older cytotoxic chemotherapy. Their overall response rate - that's defined as a complete or partial disappearance of the tumor on MRI scan - was 47% versus 11% in the control arm. When patients who had stable disease by MRI were included, 86% of those on the new combination versus 46% of those patients treated with the older chemotherapy had the so-called best clinical response. Now, a large number of patients responding to dabrafenib and trametinib, remain on treatment and are receiving these drugs with an ongoing imaging and clinical response at the time of this report. Patients receiving the new combination had a median or average progression-free survival of 20 months versus about 7.4 months with the older, standard chemotherapy. The investigators conducting this study also had patients fill out a variety of questionnaires to assess their quality of life while on treatment. Once again, the patients who received dabrafenib and trametinib, on average, experienced an improved quality of life in contrast to those on standard chemo who, on average, had a worse quality of life. The new treatment was also well-tolerated with fewer serious adverse events or side effects when compared with standard chemotherapy. And these side effects were no different than what has been seen in patients without brain tumors who have been treated with this combination, including fevers, headaches, fatigue, skin changes, and lower blood counts. The authors appropriately suggested that these findings demonstrate the importance of molecular testing of these pediatric low-grade glioma tumors at the time of diagnosis and that this combination of dabrafenib and trametinib is a new potential standard of care in those patients who have the BRAF V600E mutant, low-grade tumors. Of note, liquid formulations of these drugs have been developed for those pediatric patients who are unable to swallow capsules or tablets. The second presentation at ASCO highlighted the continued importance of prospective randomized clinical trials in patients with malignant brain tumors. Dr. Jann Sarkaria from the Mayo Clinic presented the long-awaited results of the Alliance for Clinical Trials in Oncology cooperative group phase II/III study of a PARP inhibitor or placebo added to standard temozolomide and radiation in adult patients with newly- diagnosed glioblastoma, and in addition, glioblastomas that had specific molecular finding called MGMT promoter methylation. This change to the DNA of the tumors prevents the MGMT DNA repair enzyme from being made in the tumors and leads to a better outcome with temozolomide treatment. Some very elegant laboratory science had suggested that adding a type of drug called a PARP inhibitor, which also causes defects in DNA repair, could lead to improved killing of glioblastoma tumor cells. So patients with newly- diagnosed glioblastomas, which had MGMT promoter methylation on genomic analysis, were enrolled on this study between December of 2014 and October of 2018. The study was conducted in 2 phases separated by a pre-planned pause after the first group of patients were enrolled, which was the phase II part of the study. This was done in order to allow a preliminary analysis of the outcomes of the treatment arms to make sure that there was a signal of activity that justified moving on to test this treatment in a larger number of patients, the so-called phase III part of the trial. This trial design hopes to minimize the number of patients treated with an inactive drug and save years of drug development time by avoiding large trials that go on for a long time with what turns out to be ineffective drugs. For this trial, 447 patients were eventually treated on this trial. Despite the convincing laboratory evidence and early, promising clinical results that led to the trial moving to the second or phase III portion, the final results showed no statistically significant difference in progression-free or overall survival between the 2 arms, that is, those treated with a PARP inhibitor, and those treated with placebo. I personally was very excited about this study and had hoped that the long wait to hear the results indicated that something good was happening. In addition, several of my patients who were treated on the study did exceedingly well, so I, incorrectly, it turns out, expected positive results from the trial. These negative results are a stark reminder of why we spend lots of time and money and energy performing well-designed clinical trials to determine appropriate treatment strategies for our patients, rather than relying on expert opinion or 1 institution's published experience. This approach turns out to be the best way to fairly test treatment strategies and establish new therapeutic approaches which are truly effective. A final, interesting abstract that was presented at a poster discussion session at ASCO was from the group with the University of Pennsylvania in Philadelphia, and it dealt with the risk of bleeding in patients with brain tumors who had blood clots and were then treated with a newer class of blood thinners or anticoagulants called direct oral anticoagulants, or DOACs for short. It's been known for over 100 years that a variety of types of cancer cause patients to be hypercoagulable, that is, to be predisposed to developing blood clots throughout the venous system. Patients with malignant brain tumors have the highest incidence of all tumors of developing blood clots, which typically occur in the legs, called deep venous thrombosis or DVTs, or in the lungs, called pulmonary emboli or PEs. These clots can lead to a variety of severe and debilitating symptoms, including leg pain, swelling, shortness of breath, heart strain, and even death. For the past 2 to 3 decades, affected patients have typically been treated with a class of medications called low-molecular-weight heparins, which need to be injected under the skin once or twice daily. Over the past decade, a new class of oral anticoagulants called DOACs have generally replaced low-molecular-weight heparins as the primary method of treatment for patients with and without cancer who develop venous blood clots because of their safety, ease of administration, and a lack of requirement for regular blood tests or monitoring. However, little, if any, data has been available to determine the safety of these agents in patients with brain tumors and blood clots, a situation where bleeding into the brain or the brain tumor as a side effect of the anticoagulant could be catastrophic. In fact, this potential risk led to the exclusion of patients with brain tumors from several of the large trials which established the safety of the DOACs. Despite the absence of evidence, the DOACs are now pretty broadly used in brain tumor patients for the reasons described above. So this abstract described a cohort of patients with glioblastoma who developed venous blood clots between 2014 and 2021 while under treatment at Penn. The authors reviewed the medical record to determine the relative efficacy or effectiveness and the toxicity or side effects experienced by patients treated with the low-molecular-weight heparins and with the DOACs, including the rates of bleeding into the brain or the brain tumor. 121 patients were identified who fit these criteria, and the cumulative incidence of clinically significant intracranial hemorrhage, that is, bleeding into the brain or the brain tumor, by 30 days after starting the drugs, was minimal and similar in the 2 groups. When measured at 6 months, 24% of the patients in the low-molecular-weight heparin group had developed intracranial bleeding, and 4 of those patients had died from this bleeding, while none of the 32 patients in the DOAC group experienced this complication. Thus, these investigators felt that their data suggested that there was a lower incidence of clinically important intracranial hemorrhage or bleeding in patients with glioblastoma and venous blood clots who were treated with DOACs as compared to low-molecular-weight heparin. They went on to suggest that the use of DOACs was a safe alternative in patients with glioblastoma. Now clearly, either a prospective trial, a larger trial, or additional retrospective evaluations with a larger number of patients are needed to prove the safety of this approach. But this data is pretty comforting, as the use of these agents is now widespread in patients with high-grade gliomas. The ease of administration of a pill once or twice a day, as compared with potentially lifelong injections once or twice a day, is a major quality of life advantage for our patients. Thank you for listening to this brief summary of new research in neuro-oncology from the 2022 ASCO Annual Meeting. ASCO: Thank you, Dr. Lesser. Finally, Dr. Manali Patel discusses new research focused on reducing disparities in cancer care. Dr. Patel is a medical oncologist and Assistant Professor of Medicine at Stanford University. She is also the Cancer.Net Associate Editor for Health Equity. You can view Dr. Patel's disclosures at Cancer.Net. Dr. Patel: Today I have the privilege of discussing several really exciting research abstracts that were presented at the 2022 ASCO Annual Meeting. My name is Manali Patel. I'm a thoracic oncologist, meaning I take care of patients and try to provide good care delivery for patients with lung cancer. And I also am a researcher focused on health equity. I have no relevant disclosures for any of the studies that I will be presenting today with the exception of one that I was leading. And there were several wonderful abstracts that were presented on describing disparities and the ongoing state of disparities continuing within cancer care delivery. What I was particularly struck by were many of the abstracts that I'm presenting this morning and this podcast that really focus on what we can do as a nation and what we can do individually in our clinics to try to move towards action to overcoming these inequities. The first abstract I want to present was looking at how the Affordable Care Act and changes in the Affordable Care Act led to differences in mortality or deaths by race and ethnicity following the enactment in California. And this particular study looked at greater than 150,000 people who were diagnosed with breast cancer, colorectal cancer, and cervical cancer. And they evaluated death rates from these cancers both before and after the implementation of the Affordable Care Act. And what they found was that the cancer death rates for everyone was much lower after the Affordable Care Act was passed, but specifically for individuals who had self-identified as Hispanic ethnicity, who also identified as Black and who identified as White. And so what this abstract showed me was that at a larger level and a macro level, our policies that are enforced at the national level really do play a role in terms of how we can overcome disparities in cancer. Our group, as I mentioned before, has worked on really trying to integrate community health workers into care. So this abstract paired with local union organizations in Chicago and in Atlantic City to try to help individuals who self-identified as having been from families that were from low-income households and racial and ethnic minorities to communicate their goals and their preferences for care and to also better their relationships with their clinicians as well as to describe their symptoms. And what we found in this randomized trial was that for individuals who received this community health advocate who helped them to better engage with their clinician and who also helped them to describe the symptoms that they were experiencing as well as receive community resources such as food boxes if they were food insecure or be connected to household agencies if they were having difficulties with housing, we found a significant improvement in quality of life, but we also found reductions in the use of the hospital unnecessarily. We also found that this translated into reductions in total cost of care, thereby reducing the amount of out-of-pocket costs these individuals were spending on their cancer care. One of the other abstracts that I thought really was reflective of the many different ways that we can move towards action was an abstract which looked at during the pandemic, trying to reduce the number of times people need to come in for mammograms, their biopsies, and then any further testing that they needed after their biopsy. And this particular study evaluated what was called a same-day biopsy service, which layered on a same-day mammogram reading program. So at this particular institution, they had already implemented when you came in to get your mammogram as a woman or a man, you would have a read on the same day. So you did not have to wait to find out what your results were. And what they did further to push better care was that they layered on on that same day you could get your biopsy. So almost a one-stop shop. And what they found was that for everyone, regardless of race and ethnicity, the time to biopsies decreased by almost half. And the median days, for example, from an abnormal mammogram to obtaining a biopsy, meaning a sample of that tissue, that it decreased from 10 days median to 5 days. And particular patient populations did much better. And so they were able to show that when you do interventions that move the care to provide better care for everyone, everyone benefits, but particularly our patient populations who identify as racial and ethnic minorities who were more likely to experience delays in care, they also received some benefit from this intervention. The last study I want to highlight is work which looked at how to improve specialized services for people who would otherwise not receive those. And this particular study looked at stem cell transplantation for people with blood cancers. And what they found was that these services are often only offered in very tertiary centers, so places that may not be as accessible, large institutions that a lot of people may not have access to receiving care. So what they did was they partnered with this large academic institution so that they could build a pathway for individuals who would otherwise not get stem cell transplantation so that they could have access to those services. And it was really a multipronged approach where they not only educated the clinicians in the community practice about the effort, but they also educated the institution-level clinicians about the effort. They also provided shared medical records, which oftentimes in practice, we don't share our medical records with other clinics. And what they were able to do was to convince these clinics and the institution, let's share the medical records so that then you can have access to seeing what's happening for patients that are diagnosed in the community. And then that way we can both document, we can both have access in the community as well as in the institution where they're receiving the specialized service so that there's better communication. They also provided a navigator for each patient that would help each patient to identify any sort of barriers that they may experience to receiving stem cell transplantation. And then they offered telemedicine, which allowed for individuals to receive specialized services in the comforts of their own home without having to travel after the stem cell transplantation had occurred. And what they found was that usually in the institution, most individuals were more affluent. So they had higher levels of socioeconomic status. But after the intervention, individuals that were referred from this community clinic made it such that the affluence really decreased so that it was showing that people who wouldn't otherwise have access, who had identified as having low income, were now able to receive those services and had been receiving transplantation. I think that these studies really do move us towards a new paradigm of taking action on the many disparities that we know continue to happen. I really appreciate you all for listening to this brief summary of the new research on health equity from the 2022 ASCO Annual Meeting, and I hope to see you next year. ASCO: Thank you, Dr. Patel. You can find more research from recent scientific meetings at www.cancer.net. Cancer.Net Podcasts feature trusted, timely, and compassionate information for people with cancer, survivors, and their families and loved ones. Subscribe wherever you listen to podcasts for expert information and tips on coping with cancer, recaps of the latest research advances, and thoughtful discussions on cancer care. And check out other ASCO Podcasts to hear the latest interviews and insights from thought leaders, innovators, experts, and pioneers in oncology. Cancer.Net is supported by Conquer Cancer, the ASCO Foundation, which funds lifesaving research for every type of cancer, helping people with cancer everywhere. To help fund Cancer.Net and programs like it, donate at CONQUER.ORG/Donate.

Para participar en el Congreso Emprendedor Inteligente a celebrarse en Miami el 15 y 16 de Septiembre visita www.congresoei.comSi quieres aprender de César Quintero cómo construir un negocio de coaching de más de $100,000 al año puedes verlo aquí: www.coachingalmillon.com Sobre Cristina Rodriguez Wulff https://organizatupyme.com/Instagram: @organiza.tupyme

2021, marked the 49th year since the Martial Law was introduced in the Philippines under the reign of Ferdinand Marcos. The martial law was intended to civil, stringent control and power over the people of the Philippines. In 2021, Ferdinand “Bong Bong” Marcos Jr., announced his run for presidency in the 2022 election. Critics are opposed to this move, as is Ma. Cristina Rodriguez, founder of the Bantayog ng mga Bayani Foundation, Inc. Rodriguez discusses the possible political scenarios for Ferdinand “Bong Bong” Marcos Jr. and what it will mean for the country if he does win the election. Rodriguez also discusses the impact of the Marcos' family and its psychological effect on the people of the Philippines. To watch/stream this video podcast: https://www.thenetwork.media/

It's not too often I get to interview another grappler, but today is extra special because Cristina Rodriguez not only has multiple black belts, but she also has over ten years of experience in internet marketing, and she's the founder of Grow Pro Agency. So she understands what it means to expand your niche and find new audiences. That's why episode 120 of The Digital Agency Growth Podcast is about scaling your agency through relationships! Watch our new recorded video training: Relationship-Driven New Business At-ScaleIn this episode of The Digital Agency Growth Podcast, Cristina is sharing the importance of expanding and discovering new niches and actionable steps you can take right now to help your clients give you better material to increase your success with their business. With 27 years of Martial Arts Experience and 20 years of Teaching Experience, Professor Cris Rodriguez is a 1st Degree Brazilian Jiu-Jitsu Black Belt, 3rd Degree TKD Black Belt, and Co-Owns Gracie PAC MMA, a BJJ & MMA School in Tampa, Florida, with her wife, Stephanie. In addition, she has studied Internet Marketing for the past ten years and is the Founder of Grow Pro Agency, a Digital Marketing Agency for Martial Arts Academies.Cristina and I discuss the following:How Cris decided to start an agency around online marketing after opening her own martial arts studio.How Cris handles the done for you versus the done with you models of her agency, and how best to help your clients give you better results.How Cris found her answers from her definition of success and why you shouldn't change the recipe of your mentors' to succeed.Ways Cristina's agency has scaled to 250+ clients in a year and a half in a specific niche.It's all about relationships– relationships with other businesses and the relationships with your clients. Cristina understands that, and it's helped her scale over 100% in one year. Thank you for listening! If you enjoyed this episode, please take a moment to follow, rate, and review the podcast and tell me your key takeaways!CONNECT WITH Cristina Rodriguez:Work with CrisWebsiteCONNECT WITH DAN ENGLANDER:LinkedInSales SchemaLINKS MENTIONED:7 Figure Agency Roadmap Book

Yale Law Professor Cristina Rodriguez stops by Supreme Myths to discuss her role as Co-Chair of the Supreme Court Reform Commission, immigration law, regime change in the Executive Branch, administrative law. and other fascinating issues.

Washington Post Supreme Court reporter Robert Barnes speaks with former federal judge Thomas Griffith and Yale Law School professor Cristina Rodriguez about their work on President Biden's Commission on the Supreme Court, the report the commission recently issued and the future of the high court.

Ignoring the mass market and drilling down into a niche can be a really effective targeting strategy that tends to get higher conversion rates and better results.Cristina Rodriguez has done this for years with her martial arts marketing agency, Grow Pro. In this episode Cristina explains how niches work, how to find them and target them.You can find Cristina on her website at Grow Pro Agency, Linkedin, Facebook and Twitter.Can I quickly mention is that Not Another Marketing Podcast is totally ad free and I'd love it if you could give the pod a quick shout on social media and subscribe via your podcast app.Check out more episodes at  jtid.co.uk/podcasts

Welcome to Not Another Marketing Podcast where I'm talking to Cristina Rodriguez, Founder of Grow Pro Agency, a Digital Marketing Agency for Martial Arts Academies so we're talking about marketing to a niche.

Much of the challenge with the next great technology is the ability to connect the innovation or the technology directly to the idea of changing the world. A faster cell phone, a more powerful processor, a smaller footprint all feel good, but they don't shift the power in the world to do better for all. Our guest today, Cristina Rodriguez is Vice President in Intel Corporation's Network and Edge Group and general manager of the Wireless Access Network Division see this as the moment that the traditional model should be stepped over for how ideas like the edge, latency-free and 5G all connect together and will vastly stretch technologies in this new world to directly open up opportunities for underserved communities across the globe, first and foremost. It's a unique view about how technology companies can change the velocity for their effect on the whole world by 2031.

Featuring perspectives from Dr Cristina Rodriguez, including the following topics: Case: A man in his mid-40s from Guangdong Province with nasopharyngeal carcinoma (0:00) Case: A woman in her mid-50s with secretory carcinoma with an NTRK3 ETV6 mutation (19:25) Case: A man in his mid-50s, a smoker, with recurrent metastatic laryngeal squamous cell carcinoma (33:44) CME information and select publications

Featuring a discussion on the management of head and neck cancers with Dr Cristina Rodriguez, moderated by Dr Neil Love.

Dr Cristina Rodriguez from the Fred Hutchinson Cancer Research Center in Seattle discusses the current management of head and neck cancers. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayHeadNeck21).

With 27 years of Martial Arts Experience and 20 years of Teaching Experience, Professor Cris Rodriguez is a 1st Degree Brazilian Jiu Jitsu Black Belt, 3rd Degree TKD Black Belt, and Co-Owns Gracie PAC MMA, a BJJ & MMA School in Tampa, Florida, with her wife Stephanie.She has studied Internet Marketing for the past 10 years and is the Founder of GrowPro Agency, a Digital Marketing Agency for Martial Arts Academies. As a Partner inMarketing with Schools, their core focus is to help school owners gain the freedomthey want in their business.She is also the Digital Marketing Consultant for the Martial Arts Industry Associationand runs her own Mastermind Program called “The A Team”.She earned her Elementary Education Degree from the University of SouthFlorida which has helped her to become an expert in Children's Jiu Jitsu Training &Development.https://growproagency.com

The president wields immense power to shift immigration policy and shape the lives of nearly 11 million undocumented immigrants who live in the shadow of the U.S. immigration system. Regulatory and demographic changes over the last century have resulted in a large undocumented population in America, particularly from Mexico and Central America. Without a path to legalization, undocumented immigrants remain deportable at any time and subject to the discretion of the enormous immigration enforcement bureaucracy. In part 1 of this 2-part series, Professors Adam Cox and Cristina Rodriguez, co-authors of The President and Immigration Law, explain the changes that have led to this massive shadow immigration system. They explore how the president came to sit atop a supersized enforcement bureaucracy and trace how deportation enforcement priorities have increasingly dominated U.S. immigration policy under recent administrations.

Today's Heavy Networking, sponsored by Intel, dives into 5G, virtualization, and AI. Intel's 3rd Gen Xeon processors can support a variety of use cases, including running virtualized network functions in the data center, at the edge, and in the cloud. They also have built-in acceleration for AI and cryptography, giving organizations a flexible platform for a variety of workloads, including service providers building out 5G networks. Our guest is Cristina Rodriguez, Vice President Data Center Group General Manager Wireless Access Network Division at Intel.

Today's Heavy Networking, sponsored by Intel, dives into 5G, virtualization, and AI. Intel's 3rd Gen Xeon processors can support a variety of use cases, including running virtualized network functions in the data center, at the edge, and in the cloud. They also have built-in acceleration for AI and cryptography, giving organizations a flexible platform for a variety of workloads, including service providers building out 5G networks. Our guest is Cristina Rodriguez, Vice President Data Center Group General Manager Wireless Access Network Division at Intel.

Today's Heavy Networking, sponsored by Intel, dives into 5G, virtualization, and AI. Intel's 3rd Gen Xeon processors can support a variety of use cases, including running virtualized network functions in the data center, at the edge, and in the cloud. They also have built-in acceleration for AI and cryptography, giving organizations a flexible platform for a variety of workloads, including service providers building out 5G networks. Our guest is Cristina Rodriguez, Vice President Data Center Group General Manager Wireless Access Network Division at Intel.

Today's Heavy Networking, sponsored by Intel, dives into 5G, virtualization, and AI. Intel's 3rd Gen Xeon processors can support a variety of use cases, including running virtualized network functions in the data center, at the edge, and in the cloud. They also have built-in acceleration for AI and cryptography, giving organizations a flexible platform for a variety of workloads, including service providers building out 5G networks. Our guest is Cristina Rodriguez, Vice President Data Center Group General Manager Wireless Access Network Division at Intel. The post Heavy Networking 586: Virtualizing And Accelerating 5G RAN With 3rd Gen Intel® Xeon (Sponsored) appeared first on Packet Pushers.

Today's Heavy Networking, sponsored by Intel, dives into 5G, virtualization, and AI. Intel's 3rd Gen Xeon processors can support a variety of use cases, including running virtualized network functions in the data center, at the edge, and in the cloud. They also have built-in acceleration for AI and cryptography, giving organizations a flexible platform for a variety of workloads, including service providers building out 5G networks. Our guest is Cristina Rodriguez, Vice President Data Center Group General Manager Wireless Access Network Division at Intel. The post Heavy Networking 586: Virtualizing And Accelerating 5G RAN With 3rd Gen Intel® Xeon (Sponsored) appeared first on Packet Pushers.

Today's Heavy Networking, sponsored by Intel, dives into 5G, virtualization, and AI. Intel's 3rd Gen Xeon processors can support a variety of use cases, including running virtualized network functions in the data center, at the edge, and in the cloud. They also have built-in acceleration for AI and cryptography, giving organizations a flexible platform for a variety of workloads, including service providers building out 5G networks. Our guest is Cristina Rodriguez, Vice President Data Center Group General Manager Wireless Access Network Division at Intel. The post Heavy Networking 586: Virtualizing And Accelerating 5G RAN With 3rd Gen Intel® Xeon (Sponsored) appeared first on Packet Pushers.

Kathryn talks with Becky Greenfield and Cristina Rodriguez of Wolfe Pincavage about the new normal -- working from home. They chat about how WFH has changed the way you practice and to figure out how to grow professionally in the virtual environment, and how business development plays a role in that. They discuss what firm leaders can do to better mentor team members and foster collaborative environments. Episode Resources https://wolfepincavage.com/team/becky-greenfield/ https://www.linkedin.com/in/becky-greenfield-83b0a988 https://www.linkedin.com/in/cristinarodriguez22/ https://wolfepincavage.com/team/cristina-rodriguez/  Episode Highlights Why Becky went to law school - 1:21 Why Cristina went to law school - 3:35 Taking knowledge from cases - 6:34 Moving to a more transactional firm - 7:57 A piece of advice for younger lawyers - 9:38 Law school tries to prepare you - 10:17 Your work matters - 12:33 It all depends on the type of work that you want to do - 13:50 Finding people to connect with - 16:44 How working from home has changed the way to practice - 17:37 The flexibility that it creates is fantastic but you're always “on” - 18:04 Improving opportunities for diversification - 23:01 Promoting diversity is a matter of communication - 24:13 Subscribe, Share and Review To get the next episode subscribe with your favorite podcast player. Subscribe with Apple Podcasts Follow on Spotify Leave a review on Apple Podcasts

Brad & Liz chat with Julia Callahan from Rare Bird Books and Cristina Rodriguez from A Public Space (recently of Deep Vellum Books) to talk all things "indie." And what a conversation it is! The weeds get high, and they're whacked mightily low!

What are executive orders, and how has the Biden administration used them thus far? Presidential power experts Cristina Rodriguez, author of The President and Immigration Law, and Michael McConnell, author of The President Who Would Not Be King, join host Jeffrey Rosen to answer those questions and more. They recap what they think are the most notable executive actions President Biden has taken in his first weeks in office, what their implications might be, and how they are being challenged, before reflecting on presidential power more broadly. Resources and transcript available at constitutioncenter.org/interactive-constitution/media-library Questions or comments about the show? Email us at podcast@constitutioncenter.org

What are executive orders, and how has the Biden administration used them thus far? Presidential power experts Cristina Rodriguez, author of The President and Immigration Law, and Michael McConnell, author of The President Who Would Not Be King, join host Jeffrey Rosen to answer those questions and more. They recap what they think are the most notable executive actions President Biden has taken in his first weeks in office, what their implications might be, and how they are being challenged, before reflecting on presidential power more broadly. Resources and transcript available at constitutioncenter.org/interactive-constitution/media-library Questions or comments about the show? Email us at podcast@constitutioncenter.org

The House of Representatives voted to impeach President Trump for a second time this week, with a vote of 232 in favor, 197 against, and 4 not voting. Prior to the vote, host Jeffrey Rosen sat down with two experts on the Constitution and presidential power—Cristina Rodriguez of Yale Law School and Michael McConnell of Stanford Law School. They shared their thoughts on the article of impeachment passed by the House; the charge against President Trump of incitement of insurrection in the wake of the mob invasion of the U.S. Capitol; the meaning of high crimes and misdemeanors under the Impeachment Clause; if Section 3 of the 14th Amendment should be invoked to disqualify President Trump from holding office again; how the current media and information landscape may have contributed to polarization and events culminating in the riot; what reforms might help; and more. Professor McConnell is the author of the new book The President Who Would Not be King, and professor Rodriguez is the co-author, with Adam Cox, of The President and Immigration Law. Additional resources and transcripts available at constitutioncenter.org/constitution/media-library Questions or comments about the podcast? Email us at podcast@constitutioncenter.org.

The House of Representatives voted to impeach President Trump for a second time this week, with a vote of 232 in favor, 197 against, and 4 not voting. Prior to the vote, host Jeffrey Rosen sat down with two experts on the Constitution and presidential power—Cristina Rodriguez of Yale Law School and Michael McConnell of Stanford Law School. They shared their thoughts on the article of impeachment passed by the House; the charge against President Trump of incitement of insurrection in the wake of the mob invasion of the U.S. Capitol; the meaning of high crimes and misdemeanors under the Impeachment Clause; if Section 3 of the 14th Amendment should be invoked to disqualify President Trump from holding office again; how the current media and information landscape may have contributed to polarization and events culminating in the riot; what reforms might help; and more. Professor McConnell is the author of the new book The President Who Would Not be King, and professor Rodriguez is the co-author, with Adam Cox, of The President and Immigration Law. Additional resources and transcripts available at constitutioncenter.org/constitution/media-library Questions or comments about the podcast? Email us at podcast@constitutioncenter.org.

Do you have any winter holiday traditions? This month, as we were gearing up for our holidays here at the Naked Scientists, we thought it would be a fun experiment to explore the science behind holiday celebrations around the world with the help of Chunendra Sahu, Cristina Rodriguez, Ljiljana Fruk, and Olgo Loblova - all researchers at the University of Cambridge... Like this podcast? Please help us by supporting the Naked Scientists

Do you have any winter holiday traditions? This month, as we were gearing up for our holidays here at the Naked Scientists, we thought it would be a fun experiment to explore the science behind holiday celebrations around the world with the help of Chunendra Sahu, Cristina Rodriguez, Ljiljana Fruk, and Olgo Loblova - all researchers at the University of Cambridge... Like this podcast? Please help us by supporting the Naked Scientists

Our today's guests are Cristina Rodriguez and Adam Cox. Cristina is a Professor of Law at Yale Law School. She served as Deputy Assistant Attorney General in the Office of Legal Counsel in the U.S. Department of Justice from 2011-2013. She’s also served as a term member of the Council on Foreign Relations. Adam is the Robert A. Kindler Professor of Law at New York University School of Law, where he teaches and writes about immigration law, constitutional law, and democracy. He’s also served as the Karpatkin Civil Rights Fellow for the American Civil Liberties Union, where he was involved in racial profiling and public defender reform litigation. They’re the authors of “The President and Immigration Law,” which analyzes the historical and structural sources that explain the President’s overwhelming power over immigration policy. It’s a wonderful analysis of history, policy, and the Constitution.

On this episode of the Futurum Tech Podcast - Interview Series I am joined by Cristina Rodriguez, Vice President for the Data Center Group and General Manager of the Wireless Access Network Division for Intel. Cristina is part of the global organization that is driving change through 5G network build-out, edge computing, improving AI, and improving radio access networks. It's an exciting space to be in right now as the demand for faster networks and easier access to data increases across enterprise organizations.    Our conversation covered several aspects of network transformation including a broad overview of digital connectivity and networking. We also explored how Intel has focused on the transformation of the network and the importance of that role this year. 2020, while crazy in a lot of aspects, really created new opportunities for the growth of 5G and network transformation.   The Transformation of Network Infrastructure   My conversation with Cristina also revolved around the following:   How virtualization and transformation of the network will enable opportunities in the future. The role Intel has played in transforming the network architecture from core to edge to access. Specifically the few things the company has focused on in the last few years to deliver this transformation to customers. An exploration of the partnerships Intel has made to achieve the core to edge network transformation. Intel's thinking around RAN transformation and what they anticipate for 2021. A brief overview of Intel's partnerships with Amdocs, Verizon and VMware.   Where We Go From Here   2020 proved that we need faster connectivity speeds which means we need better networks and stronger infrastructure. Intel realizes this and is partnering with various organizations to build and deliver the solutions that we need. If you'd like to read more about what Intel is doing in this area, check out their website. These changes will impact all of us in the coming years. If you are involved in network transformation in your organization make sure to put this on your ‘must listen' list.   Disclaimer: This show is for information and entertainment purposes only. While we will discuss publicly traded companies on this show, the contents of this show should not be taken as investment advice.

Law professors Adam Cox (NYU) and Cristina Rodriguez (Yale) offer a revisionist view of presidential authority in their new book The President and Immigration Law. Through authority delegated by federal statutes as well as power to decide who among a population of more than 10 million undocumented migrants should be removed or permitted to stay, the President, they argue, is in fact a "co-principal" with Congress in the making of U.S. immigration law and policy.

The biggest immigration controversies of the last decade have involved policies produced by presidents. Earlier this month, legal scholars Cristina Rodriguez, Adam Cox, and Michael McConnell joined National Constitution Center President and CEO Jeffrey Rosen to explore some of those controversies and consider what the president’s role in immigration law has been and should be, what the Constitution says, and how Congress fits in. Rodriguez and Cox are co-authors of the new book The President and Immigration Law.  Questions or comments about the show? Email us at podcast@constitutioncenter.org.

Season 12 of the Two Month Review kicked off with Cristina Rodriguez from Deep Vellum Bookstore joining Chad and Brian to talk about the first section of Mónica Ramón Ríos and Robin Myers's Cars on Fire. They talk about The Gits, "Dead Men Don't Rape," the connections between academy and power structures, how "timely" this connection is, the clarity of the prose, and much more. In honor of Mia Zapata, this week's music is "Another Shot of Whiskey" by The Gits. If you'd prefer to watch the conversation, you can find it on YouTube along with all our past episodes. The next broadcast will be on June 10th. Mónica Ramón Ríos will be the special guest, and we'll focus on pages 64-151. Follow Open Letter, Chad Post, and Brian Wood for random thoughts and information about upcoming guests. Be sure to order Brian's book, Joytime Killbox, which is now officially available at better bookstores everywhere thanks to BOA Editions. And you can get 20% off Cars on Fire by using the code 2MONTH at checkout. (Offer only good in the U.S., since we can't ship overseas, but to be honest, we can't ship right now! Order it from Bookshop.org.) You can also support this podcast and all of Open Letter's activities by making a tax-deductible donation through the University of Rochester.

Season 12 of the Two Month Review kicked off with Cristina Rodriguez from Deep Vellum Bookstore joining Chad and Brian to talk about the first section of Mónica Ramón Ríos and Robin Myers's Cars on Fire. They talk about The Gits, "Dead Men Don't Rape," the connections between academy and power structures, how "timely" this connection is, the clarity of the prose, and much more.  In honor of Mia Zapata, this week's music is "Another Shot of Whiskey" by The Gits. If you'd prefer to watch the conversation, you can find it on YouTube along with all our past episodes. The next broadcast will be on June 10th. Mónica Ramón Ríos will be the special guest, and we'll focus on pages 64-151. Follow Open Letter, Chad Post, and Brian Wood for random thoughts and information about upcoming guests. Be sure to order Brian's book, Joytime Killbox, which is now officially available at better bookstores everywhere thanks to BOA Editions. And you can get 20% off Cars on Fire by using the code 2MONTH at checkout. (Offer only good in the U.S., since we can't ship overseas, but to be honest, we can't ship right now! Order it from Bookshop.org.) You can also support this podcast and all of Open Letter's activities by making a tax-deductible donation through the University of Rochester.

On this episode, our CEO Suzanne Nossel addresses questions about government surveillance, White House retaliation against journalism, and imprisoned writers globally in our weekly TOUGH QUESTIONS segment. Then, Will Evans and Cristina Rodriguez from bookseller Deep Vellum in Dallas talk about how they are keeping the literary community in Texas vibrant --- Send in a voice message: https://anchor.fm/penamerica/message Support this podcast: https://anchor.fm/penamerica/support

A bit of an experimental episode, Chad is joined by five indie booksellers to talk about the "new normal," fears of reopening, what booksellers are doing now, and—most importantly—actual books. The complete rundown of recommendations is below, but one note: please buy these titles from the bookseller who recommended them. Sparks said it diplomatically at the end, but if at all possible, order directly, not through Bookshop.org. (Although given that zero Open Letter books were plugged, maybe you should buy our books only from Amazon? KIDDING. Buy them from Bookshop.org.) Also, if you like this podcast and all the free programming that Open Letter/Three Percent provides, consider donating to us as well. You have to write us in on that U of R form so that the money comes directly to Open Letter, but we absolutely need your support right now. (Especially as Chad tries to figure out the future with no employees for part of the summer . . . Yay mandatory furloughs!) Anyway, here are the recommendations, with links directly to the store recommending said title:   Emma Ramadan, Riffraff The Word Pretty by Elisa Gabbert (Black Ocean) Pizza Girl: A Novel by Jean Kyoung Frazier (Doubleday) That Time of Year by Marie NDiaye, translated from the French by Jordan Stump (or "Stumps" if you believe Amazon) (Two Lines)   Shuchi Saraswat, Brookline Booksmith Calamities by Renee Gladman (Wave Books) Territory of Light by Yuko Tsushima (Picador) Minor Detail by Adania Shibli, translated from the Arabic by Elisabeth Jaquette (New Directions)   Nick Buzanski, Books Are Magic Luminous Republic by Andres Barba, translated from the Spanish by Lisa Dillman (Houghton Mifflin Harcourt) All My Cats by Bohumil Hrabal (New Directions) On Lighthouses by Jazmina Barrera, translated from the Spanish by Christina MacSweeney (Two Lines)   Stephen Sparks, Point Reyes Books The Unseen by Roy Jacobsen, translated from the Norwegian by Don Shaw and Don Bartlett (Biblioasis) Grove by Esther Kinsky, translated from the German by Caroline Schmidt (Transit)   Cristina Rodriguez, Deep Vellum Books throughsmoke by Jehanne Dubrow (New Rivers Press) Cockfight by María Fernanda Ampuero, translated from the Spanish by Frances Riddle (Feminist Press) Ancestry of Objects by Tatiana Ryckman (Deep Vellum)   As always, feel free to send any and all comments or questions to: threepercentpodcast@gmail.com. Also, if there are articles you’d like us to read and analyze (or just make fun of), send those along as well. And if you like the podcast, tell a friend and rate us or leave a review on iTunes! You can also follow Open Letter, Riffraff, and Chad on Twitter and Instagram (OL, Riffraff, Chad) for book and baseball talk. If you don’t already subscribe to the Three Percent Podcast you can find us on iTunes, Stitcher, and other places. Or you can always subscribe by adding our feed directly into your favorite podcast app: http://threepercent.libsyn.com/rss

In this Intel Chip Chat audio podcast with Allyson Klein: On this episode of Chip Chat, Cristina Rodriguez, Vice President in the Data Center Group and General Manager of the Wireless Access Network Division at Intel, talks with host Allyson Klein about Intel’s expanding network portfolio. Rodriguez discusses the company’s unique vision of a fully […]

In this Intel Chip Chat audio podcast with Allyson Klein: On this episode of Chip Chat, Cristina Rodriguez, Vice President in the Data Center Group and General Manager of the Wireless Access Network Division at Intel, talks with host Allyson Klein about Intel’s expanding network portfolio. Rodriguez discusses the company’s unique vision of a fully […]

In this Intel Chip Chat audio podcast with Allyson Klein: On this episode of Chip Chat, Cristina Rodriguez, Vice President in the Data Center Group and General Manager of the Wireless Access Network Division at Intel, talks with host Allyson Klein about Intel’s expanding network portfolio. Rodriguez discusses the company’s unique vision of a fully […]

On this episode of Chip Chat, Cristina Rodriguez, Vice President in the Data Center Group and General Manager of the Wireless Access Network Division at Intel, talks with host Allyson Klein about Intel’s expanding network portfolio. Rodriguez discusses the company’s unique vision of a fully connected, intelligent network from cloud to edge. As analysts are forecasting that millions of new 5G base stations will need to be deployed in the coming years to expand customer services, Intel is engaging with the broader network industry to create solutions that can scale across all types of radio access network (RAN) deployments. Rodriguez goes into detail about how Intel collaborated with the world’s 5G leaders to design standard, high-volume silicon for RAN deployment with the new 10nm Intel® Atom® P 5900 and the deep investments Intel has made in software. To learn more about Intel’s network portfolio, visit intel.com/network and follow Cristina Rodriguez on Twitter at @cristinar_5g. Notices & Disclaimers Intel technologies may require enabled hardware, software or service activation. No product or component can be absolutely secure. Your costs and results may vary. © Intel Corporation. Intel, the Intel logo, and other Intel marks are trademarks of Intel Corporation or its subsidiaries. Other names and brands may be claimed as the property of others.

Cristina Rodriguez, Vice President for the Data Platforms Group and General Manager for the Wireless Access Network Division for Intel, joins Chip Chat to update on the evolution of compute infrastructure for the network edge. Rodriguez leads Intel's efforts to provide innovative Wireless Access Network solutions, including those for 5G. 5G deployments are a significant area of focus for the communications industry, with Gartner predicting greater than $4 billion in 5G infrastructure spending in 2020 alone[1]. In this interview, Rodriguez and host Allyson Klein dive into Intel's strategy for enabling new edge and 5G use cases. Rodriguez notes that while 5G and the big data explosion enable new opportunities for service providers, these opportunities often depend on low latency and high reliability in the wireless network. This means moving more compute closer to the edge, where the data is being generated, and harnessing virtualization and cloud architectures throughout the network, from data center to core to edge. Rodriguez highlights recent successful deployments, including Corning's strategic collaboration with Intel to scale 5G in-building network solutions[2] and New Jersey's American Dream shopping and entertainment complex, an outdoor deployment powered by JMA Wireless XRAN and Intel Xeon Scalable processors which is one of the first FCC-authorized commercial deployments using the new Citizens Broadband Radio Service (CBRS) spectrum at 3.5 GHz. Finally, Rodriguez reviews Intel's portfolio of hardware and software solutions for the edge, including the upcoming Snow Ridge solution for 5G radio access networks. First announced with Intel's customers Ericsson and ZTE at Mobile World Congress 2019, Snow Ridge is a 10nm multi-core system on a chip (SoC) with integrated network acceleration that extends Intel architecture into wireless base stations for 5G and edge compute. Intel's base station partners are already developing solutions leveraging this leading part, which will launch at MWC 2020. For more information on Intel solutions for 5G and the network edge, please visit https://intel.com/network and follow along on Twitter with https://twitter.com/intel5gnetworks and https://twitter.com/CristinaR_5G. [1] https://channellife.com.au/story/gartner-5g-infrastructure-revenue-to-reach-us-4b-in-2020 [2] https://www.corning.com/worldwide/en/about-us/news-events/news-releases/2019/10/corning-announces-5g-in-building-network-collaboration-with-intel.html Intel technologies' features and benefits depend on system configuration and may require enabled hardware, software or service activation. Performance varies depending on system configuration. No product or component can be absolutely secure. Check with your system manufacturer or retailer or learn more at intel.com. Intel, the Intel logo, and Xeon are trademarks of Intel Corporation or its subsidiaries in the U.S. and/or other countries. *Other names and brands may be claimed as the property of others. © Intel Corporation

Este es el cuadragésimo sexto capítulo de textos para compartir. En este caso te vas a enterar “¿Por qué se huelen la cola los perros?” una leyenda de Cristina Rodriguez Lomba especial para los más chiquitos de la casa Autora: Cristina Rodriguez Lomba Textos para compartir en Youtube Canal: http://www.youtube.com/c/TextosparaCompartir Diseño gráfico: Diego Tapia Producción musical: Natalia Tapia Voz: Raúl Tapia Canal: https://www.youtube.com/channel/UCR2Ji1pQcQicFJZeJApxRDg Vías de comunicación Correo: contacto.textosparacompartir.com Redes sociales: Fan Page: https://www.facebook.com/textosparacompartirOK/ Facebook: https://www.facebook.com/raultapia04 Instagram: https: //www.instagram.com/raultapia04 ...

Neste episódio participamos do evento Clínica do Amanhã em São Paulo, realizado anualmente pelo Dr. Fernando Cembranelli. Entrevistamos StartUps e Empreendedores, para ficarmos por dentro das inovações que estão ocorrendo na área da saúde. Então, na segunda parte do Giro SD você vai conhecer: Lasse Koivisto CEO da Prontmed, Fabiana de Almeida, fisioterapeuta  e fundadora da Techbalance e Cristina Rodriguez, dentista e  COO da  Health Nova Hub.Além disso você vai ouvir o Pitch de uma das maiores empresas de Impressão 3D do mundo, a Materialise. Quem apresenta é o Pos - Doc Bruno Barreto. Está demais! Coloque o seu fone de ouvido e curta o som! Cadastre - se gratuitamente no Saúde Digital On Demand Conheça por dentro da nossa comunidade de early adopters! Lá você pode se atualizar com as tendências e inovações do setor da saúde, e além disso você vai aprender na prática com quem está fazendo a diferença e protagonizando a transformação digital da saúde. Clique aqui para conhecer o Saúde Digital On Demand. Não fique para trás! Fique Up To Date no SDOD! A Prontmed é um prontuário eletrônico feito de médicos para médicos. Através de dados clínicos estruturados é possível promover uma melhor gestão da saúde para que o paciente receba o melhor cuidado possível.  A Prontmed não é apenas um prontuário eletrônico é uma ferramenta que auxilia o médico a tomar uma melhor decisão. O software não é apenas um prontuario eletrônico, tem que ser uma ferramente que auxilia a tomar uma melhor decisão. Além disso promove um aumento de 30% na produtividade diária e ainda 50% de redução no tempo de prescrição e solicitação de exames. Fabiana de Almeida é fisioterapeuta e conhecendo os problemas causados por quedas em seus pacientes idosos, fundou a  Techbalance. A empresa tem como objetivo a  prevenção de quedas em idosos, através de um aplicativo para celular que mede o risco de quedas. Através do aplicativo é possível prever o risco de quedas e acompanhar a recuperação do paciente. Além disso ele pode ser usado em pacientes internados ou não internados, ajudando a garantir independência e qualidade de vida. Health Nova Hub,  é um Hub de inovação em saúde, uma rede com o propósito de abrigar, fomentar e desenvolver uma comunidade de empreendedores e inovadores nesta área. O Saúde Digital entrevistou a Cristina Rodriguez, que é dentista e COO do Health Nova Hub. Além de empreendedora, Cristina é professora de Gestão Odontológica na FOUNIP  e destaca a importância dessa matéria nos currículos da graduação, além da raridade dessa disciplina nos cursos existentes. Links citados no episódio:  Materialise - https://www.materialise.com/ Prontmed - http://www.prontmed.com/site/ Techbalance- https://www.techbalance.com.br/ Health Inova Hub - http://healthinnovahub.com/2018/ Participe do Saúde Digital Podcast Deixe-nos saber o que você achou desse episódio! Você tem alguma dica para dar para o Saúde Digital podcast? Quer sugerir um tema? Sua participação é muito importante! Clique aqui para falar conosco. Você pode falar também diretamente com o host Lorenzo Tomé pelo Instagram, Linkedln ou Telegram no @lorenzotome Música usada no episódio: Story by Declan DP https://soundcloud.com/declandp Licensing Agreement 2.0 (READ) http://www.declandp.info/music-licensing 

This podcast is to spread awareness about the March of Dimes and what the organizations mission is to prevent preterm birth worldwide.

Cristina Rodriguez is the Vice President of Intel’s Data Center Group and General Manager of the Wireless Access Network Division. She sits down with Allyson Klein in this episode of Chip Chat to talk about the transformation of the radio access network to support commercial 5G deployments around the globe. 5G services demand a new architectural approach for radio access networks. Communication service providers are not taking a one-size-fits-all approach to this transformation. Instead they are evaluating a mix of approaches, including traditional distributed, fully or centralized virtualization, integrated, micro cells and more. This pragmatic view positions CommSPs to leverage existing investments while introducing cloud architectural concepts. Similarly Intel takes a holistic solution view of each deployment that draws on a broad portfolio of high performance CPUs, SOCs with network acceleration, eASIC, FPGAs, software, storage and more. Cristina details the new “Snow Ridge” 10-nm SOC that extends Intel architecture into 5G wireless access base stations for control and packet processing and will establish new performance per watt leadership. Ericsson is already planning to deploy Snow Ridge in its portfolio of solutions. She also highlights some of the recent innovations in FlexRAN to bring cloud innovation to the radio access network in the form of SDN, NFV, Multi-access Edge Computing (MEC), network slicing and more. She also touches on the momentum and maturity in ecosystem solutions intended to accelerate adoption across the market. Rodriguez also shares some of the new 5G use cases in industrial, retail, entertainment and other industries that are making the previously impossible, possible. These use cases are made possible by transformed networks, and her team’s work in RAN will play a key role in this end-to-end transformation. Intel technologies' features and benefits depend on system configuration and may require enabled hardware, software or service activation. Performance varies depending on system configuration. No product or component can be absolutely secure. Check with your system manufacturer or retailer or learn more at intel.com. Intel and the Intel logo are trademarks of Intel Corporation or its subsidiaries in the U.S. and/or other countries. *Other names and brands may be claimed as the property of others. © Intel Corporation

Stage and Screen star Sutton Foster talks about her role with the 15th annual Christmas with the Mormon Tabernacle Choir. Broadway and television star, Kristen Sieh, who plays Iris in "The Band's Visit" discusses her role as a new mom in the show. Senior Editor of Travelzoo, Gabe Saglie, introduces us to their holiday travel guide, where to splurge and where to save this holiday season. Cristina Rodriguez, Coors Light Líder of the Year; President and Co-Founder, Mind & Melody, Inc. talks about how important music is for young kids and the elderly.

Transformando vidas a través de la músicaHoy les platicamos sobre un programa que está destacando a líderes latinos por su trabajo en la comunidad. Cristina Rodríguez es la ganadora del Premio Coors Light 2018.. nos cuenta lo que eso significa para ella y su organización “Mind & Melody” y también qué satisfacciones le deja ser voluntaria.

In a special episode recorded live at Slate Day during Tribfest in Austin,  Dahlia Lithwick is joined by Angela Onwuachi-Willig, Dean of Boston University Law School, Cristina Rodriguez, Leighton Homer Surbeck professor of law at Yale Law School, Stephen Vladeck, A. Dalton Cross professor of law at the University of Texas Law School and Adam White, director of the Center for the Study of the Administrative State at George Mason University’s Antonin Scalia Law School for a deep dive on the fallout from the Kavanaugh hearings and the future of the Supreme Court absent a swing justice. Please let us know what you think of Amicus. Join the discussion of this episode on Facebook. Our email is amicus@slate.com.Podcast production by Sara Burningham. Learn more about your ad choices. Visit megaphone.fm/adchoices

In a special episode recorded live at Slate Day during Tribfest in Austin,  Dahlia Lithwick is joined by Angela Onwuachi-Willig, Dean of Boston University Law School, Cristina Rodriguez, Leighton Homer Surbeck professor of law at Yale Law School, Stephen Vladeck, A. Dalton Cross professor of law at the University of Texas Law School and Adam White, director of the Center for the Study of the Administrative State at George Mason University’s Antonin Scalia Law School for a deep dive on the fallout from the Kavanaugh hearings and the future of the Supreme Court absent a swing justice. Please let us know what you think of Amicus. Join the discussion of this episode on Facebook. Our email is amicus@slate.com.Podcast production by Sara Burningham. Learn more about your ad choices. Visit megaphone.fm/adchoices

Esta semana nos visitó Cristina Rodriguez, CEO de Mumablue, la startup madrileña que personaliza libros infantiles.

On GPS, the new Watergate? Fareed is joined by Michael Hayden, James Woolsey and others to discuss what happens after Trump firing of James Comey, the man in charge if getting to the bottom of Russian collusion in the American election. And, how did Venezuela go from oil-rich nation to the brink of collapse? Finally on Mother's Day, a look at the Biblical first mother: Eve. Guests include: Michael Hayden, James Woolsey, Cristina Rodriguez, Tim Naftali, Moises Naim, Shannon O'Neil and Bruce Feiler

Elizabeth Price Foley of Florida International University and Cristina Rodriguez of Yale University discuss President Trump's executive order on immigration and how Congress could respond to sanctuary cities going forward. Continue today’s conversation on Facebookand Twitter using @ConstitutionCtr. We want to know what you think of the podcast! Email us at editor@constitutioncenter.org. Sign up to receive Constitution Weekly, our email roundup of constitutional news and debate, at bit.ly/constitutionweekly. Please subscribe to We the People and our companion podcast, Live at America’s Town Hall, on iTunes, Stitcher, or your favorite podcast app. We the People is a member of Slate’s Panoply network. Check out the full roster of podcasts at Panoply.fm. Despite our congressional charter, the National Constitution Center is a private nonprofit; we receive little government support, and we rely on the generosity of people around the country who are inspired by our nonpartisan mission of constitutional debate and education. Please consider becoming a member to support our work, including this podcast. Visit constitutioncenter.org to learn more. This show was engineered by Kevin Kilbourne and produced by Nicandro Iannacci. Research was provided by Lana Ulrich and Tom Donnelly. The host of We the People is Jeffrey Rosen.

Elizabeth Price Foley of Florida International University and Cristina Rodriguez of Yale University discuss President Trump's executive order on immigration and how Congress could respond to sanctuary cities going forward. Continue today’s conversation on Facebookand Twitter using @ConstitutionCtr. We want to know what you think of the podcast! Email us at editor@constitutioncenter.org. Sign up to receive Constitution Weekly, our email roundup of constitutional news and debate, at bit.ly/constitutionweekly. Please subscribe to We the People and our companion podcast, Live at America’s Town Hall, on iTunes, Stitcher, or your favorite podcast app. We the People is a member of Slate’s Panoply network. Check out the full roster of podcasts at Panoply.fm. Despite our congressional charter, the National Constitution Center is a private nonprofit; we receive little government support, and we rely on the generosity of people around the country who are inspired by our nonpartisan mission of constitutional debate and education. Please consider becoming a member to support our work, including this podcast. Visit constitutioncenter.org to learn more. This show was engineered by Kevin Kilbourne and produced by Nicandro Iannacci. Research was provided by Lana Ulrich and Tom Donnelly. The host of We the People is Jeffrey Rosen.

Replaying the "Best Of" It's Everything With Bebe Sweetbriar's Show(IEWBS) Bebe on the history of Folsom Street Fair and guests, Bianca Stevens and Cristina Rodriguez from AsiaSF. Following their interview is a conversation about USA Rugby and International Gay Rugby Memorandum to eliminate homophobia in rugby.

It's Everything With Bebe Sweetbriar's Show (IEWBS) on the history of Folsom Street Fair and guests, Bianca Stevens and Cristina Rodriguez from AsiaSF. Following their interview is a conversation about USA Rugby and International Gay Rugby Memorandum to eliminate homophobia in rugby.

Becky Harks, the blogger behind Mommy Wants Vodka hosts a 30 minute chat with Cristina Rodriguez, the Vehicle Dynamics Development Engineer for Ford Motor Company. Listen as Becky and Cristina discuss car maintenance myths and a few tricks on how to negotiate with car mechanics.

Cristina Rodriguez, Professor of Law at New York University Law School, discusses how the political, legal, and cultural burdens should be distributed and shared to help countries manage the change produced by immigration.